S. Tolaney

Oncology · 2013–2021

A researcher in the Science corpus: 9 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom S. Tolaney trusts

Their strongest outbound trust, strongest first, inferred from their citations.

  1. D. Pardoll (in Oncology)

Papers from S. Tolaney's perspective

Ordered by how strongly the researchers S. Tolaney trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma (Clinical Cancer Research)
  2. The blockade of immune checkpoints in cancer immunotherapy (Nature Reviews. Cancer)
  3. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  4. Cell cycle, CDKs and cancer: a changing paradigm (Nature Reviews. Cancer)
  5. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. (Journal of Clinical Oncology)
  6. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. (Journal of Clinical Oncology)
  7. Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis (Journal of immunotherapy)
  8. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence (Clinical Cancer Research)
  9. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 (JAMA Oncology)
  10. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer (npj Breast Cancer)

Their papers